IBRX Investors Eligible to Lead Fraud Lawsuit

The Rosen Law Firm filed the first securities fraud case against ImmunityBio.

Apr. 12, 2026 at 2:44am

Got story updates? Submit your updates here. ›

A minimalist studio still life featuring a stack of financial documents, a calculator, and a gavel floating on a clean, monochromatic background, conceptually representing the abstract themes of corporate strategy, finance, and legal proceedings.A legal battle over alleged financial misconduct could have far-reaching implications for investors in the biotech sector.NYC Today

The Rosen Law Firm, a global investor rights law firm, is reminding purchasers of ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026 that they have the opportunity to lead a securities fraud lawsuit against the company.

Why it matters

This lawsuit alleges that ImmunityBio made false and misleading statements about its business and financial condition, which could have significant implications for investors who purchased the company's securities during the specified time period.

The details

The lawsuit alleges that ImmunityBio misled investors about the progress and prospects of its COVID-19 vaccine candidate, as well as the company's overall financial health. The Rosen Law Firm is seeking to represent investors who may have been harmed by these alleged misrepresentations.

  • The class period for the lawsuit is from January 19, 2026 to March 24, 2026.
  • The Rosen Law Firm filed the first securities fraud case against ImmunityBio on April 11, 2026.

The players

Rosen Law Firm

A global investor rights law firm that has filed the first securities fraud lawsuit against ImmunityBio.

ImmunityBio, Inc.

A biopharmaceutical company that is accused of making false and misleading statements about its business and financial condition.

Got photos? Submit your photos here. ›

What’s next

The judge will set a deadline of May 12, 2026 for investors to file to become the lead plaintiff in the case.

The takeaway

This lawsuit highlights the importance of transparency and accurate disclosures for publicly traded companies, as investors rely on this information to make informed decisions. The outcome of this case could have broader implications for the biopharmaceutical industry.